The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Assessing the clinical utility of cancer genomic and proteomic data across tumor types
Open accessAbstract
Molecular profiling of tumors promises to advance the clinical management of cancer, but the benefits of integrating molecular data with traditional clinical variables have not been systematically studied. Here we retrospectively predict patient survival using diverse molecular data (somatic copy-number alteration, DNA methylation and mRNA, microRNA and protein expression) from 953 samples of four cancer types from The Cancer Genome Atlas project. We find that incorporating molecular data with clinical variables yields statistically significantly improved predictions (FDR < 0.05) for three cancers but those quantitative gains were limited (2.2–23.9%). Additional analyses revealed little predictive power across tumor types except for one case. In clinically relevant genes, we identified 10,281 somatic alterations across 12 cancer types in 2,928 of 3,277 patients (89.4%), many of which would not be revealed in single-tumor analyses. Our study provides a starting point and resources, including an open-access model evaluation platform, for building reliable prognostic and therapeutic strategies that incorporate molecular data.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression shrinkage and selection via the lasso
Tibshirani, R. (1996) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1996.tb02080.x · Cited by 51,482
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Integrated genomic characterization of endometrial carcinoma
The Cancer Genome Atlas Research Network, & Levine, D. A. (2013) · Nature · doi:10.1038/nature12113 · Cited by 5,784
Comprehensive genomic characterization of squamous cell lung cancers
The Cancer Genome Atlas Research Network (2012) · Nature · doi:10.1038/nature11404 · Cited by 3,994
Mermel, C. H., Schumacher, S. E., Hill, B., Meyerson, M. L., Beroukhim, R., & Getz, G. (2011) · Genome Biology · doi:10.1186/gb-2011-12-4-r41 · Cited by 3,550
Self-citationComprehensive molecular characterization of clear cell renal cell carcinoma
The Cancer Genome Atlas Research Network (2013) · Nature · doi:10.1038/nature12222 · Cited by 3,485
Ishwaran, H., Kogalur, U. B., Blackstone, E. H., & Lauer, M. S. (2008) · The Annals of Applied Statistics · doi:10.1214/08-aoas169 · Cited by 2,714
Christakis, D., Richards, J. A., Zimmerman, F. J., Garrison, M. M., Xu, D., & Yapanel, U. H. (2009) · Cited by 2,289
Metagenes and molecular pattern discovery using matrix factorization
Brunet, J.-P., Tamayo, P., Golub, T. R., & Mesirov, J. P. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308531101 · Cited by 2,183
Douillard, J.-Y., Rosell, R., De Lena, M., Carpagnano, F., Ramlau, R., Gonzáles-Larriba, J. L., Grodzki, T., Pereira, J. R., Le Groumellec, A., Lorusso, V., et al. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70804-x · Cited by 1,573
Ishwaran, H., Kogalur, U. B., Blackstone, E. H., & Lauer, M. S. (2008) · Cited by 1,310
Sturgeon, C. M., Duffy, M. J., Stenman, U.-H., Lilja, H., Brünner, N., Chan, D. W., Babaian, R., Bast, R. C., Dowell, B., Esteva, F. J., et al. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2008.105601 · Cited by 1,129
Heng, D. Y., Xie, W., Regan, M. M., Harshman, L. C., Bjarnason, G. A., Vaishampayan, U. N., Mackenzie, M., Wood, L., Donskov, F., Tan, M.-H., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70559-4 · Cited by 1,030
Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis
Krueger, D. A., Care, M. M., Holland, K., Agricola, K., Tudor, C., Mangeshkar, P., Wilson, K. A., Byars, A., Sahmoud, T., & Franz, D. N. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001671 · Cited by 1,006
The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
Van Allen, E. M., Wagle, N., Sucker, A., Treacy, D. J., Johannessen, C. M., Goetz, E. M., Place, C. S., Taylor-Weiner, A., Whittaker, S., Kryukov, G. V., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0617 · Cited by 912
Self-citationMAQC Consortium (2010) · Nature Biotechnology · doi:10.1038/nbt.1665 · Cited by 889
Glioblastoma survival in the United States before and during the temozolomide era
Johnson, D. R., & O’Neill, B. P. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0749-4 · Cited by 720
Genome Sequencing Identifies a Basis for Everolimus Sensitivity
Iyer, G., Hanrahan, A. J., Milowsky, M. I., Al-Ahmadie, H., Scott, S. N., Janakiraman, M., Pirun, M., Sander, C., Socci, N. D., Ostrovnaya, I., et al. (2012) · Science · doi:10.1126/science.1226344 · Cited by 690
Jänne, P. A., Shaw, A. T., Pereira, J. R., Jeannin, G., Vansteenkiste, J., Barrios, C., Franke, F. A., Grinsted, L., Zazulina, V., Smith, P., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70489-8 · Cited by 655
Van Allen, E. M., Wagle, N., Stojanov, P., Perrin, D. L., Cibulskis, K., Marlow, S., Jane-Valbuena, J., Friedrich, D. C., Kryukov, G., Carter, S. L., et al. (2014) · Nature Medicine · doi:10.1038/nm.3559 · Cited by 546
Self-citationWagle, N., Berger, M. F., Davis, M. J., Blumenstiel, B., DeFelice, M., Pochanard, P., Ducar, M., Van Hummelen, P., MacConaill, L. E., Hahn, W. C., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0184 · Cited by 533
Self-citationCurrent and emerging biomarkers in breast cancer: prognosis and prediction
Weigel, M. T., & Dowsett, M. (2010) · Endocrine-Related Cancer · doi:10.1677/erc-10-0136 · Cited by 496
Wagle, N., Van Allen, E. M., Treacy, D. J., Frederick, D. T., Cooper, Z. A., Taylor-Weiner, A., Rosenberg, M., Goetz, E. M., Sullivan, R. J., Farlow, D. N., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0631 · Cited by 478
Self-citationKim, K. B., Kefford, R., Pavlick, A. C., Infante, J. R., Ribas, A., Sosman, J. A., Fecher, L. A., Millward, M., McArthur, G. A., Hwu, P., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.5966 · Cited by 477
Self-citationProfiling Critical Cancer Gene Mutations in Clinical Tumor Samples
MacConaill, L. E., Campbell, C. D., Kehoe, S. M., Bass, A. J., Hatton, C., Niu, L., Davis, M., Yao, K., Hanna, M., Mondal, C., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007887 · Cited by 438
Self-citationGenomics-Driven Oncology: Framework for an Emerging Paradigm
Garraway, L. A. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.8934 · Cited by 340
Self-citationWagle, N., Grabiner, B. C., Van Allen, E. M., Hodis, E., Jacobus, S., Supko, J. G., Stewart, M., Choueiri, T. K., Gandhi, L., Cleary, J. M., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0353 · Cited by 281
Self-citationKallakury, B., Karikehalli, S., Haholu, A., Sheehan, C. E., Azumi, N., & Ross, J. S. (2001) · PubMed · Cited by 280
Berchuck, A., Iversen, E. S., Lancaster, J. M., Pittman, J., Luo, J., Lee, P., Murphy, S., Dressman, H. K., Febbo, P. G., West, M., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2398 · Cited by 266
Publication of Tumor Marker Research Results: The Necessity for Complete and Transparent Reporting
McShane, L. M., & Hayes, D. F. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.6858 · Cited by 185
MicroRNA Let-7f Inhibits Tumor Invasion and Metastasis by Targeting MYH9 in Human Gastric Cancer
Liang, S., He, L., Zhao, X., Miao, Y., Gu, Y., Guo, C., Xue, Z., Dou, W., Hu, F., Wu, K., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018409 · Cited by 181
Khella, H. W. Z., Bakhet, M., Allo, G., Jewett, M. A. S., Girgis, A. H., Latif, A., Girgis, H., Von Both, I., Bjarnason, G. A., & Yousef, G. M. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt184 · Cited by 164
Characteristics of Lung Cancers Harboring NRAS Mutations
Ohashi, K., Sequist, L. V. D., Arcila, M. E., Lovly, C. M., Chen, X., Rudin, C. M., Morán, T., Camidge, D. R., Vnencak‐Jones, C. L., Berry, L. D., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3173 · Cited by 153
Henry, N. L., & Hayes, D. F. (2006) · The Oncologist · doi:10.1634/theoncologist.11-6-541 · Cited by 149
Up-Regulation of MicroRNA-21 Correlates with Lower Kidney Cancer Survival
Zaman, M. S., Shahryari, V., Deng, G., Thamminana, S., Saini, S., Majid, S., Chang, I., Hirata, H., Ueno, K., Yamamura, S., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031060 · Cited by 146
Clinical Analysis and Interpretation of Cancer Genome Data
Allen, E. M. V., Wagle, N., & Levy, M. A. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.48.7215 · Cited by 136
Self-citationMargolin, A. A., Bilal, E., Huang, E. S., Norman, T., Ottestad, L., Mecham, B. H., Sauerwine, B., Kellen, M., Mangravite, L. M., Furia, M. D., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006112 · Cited by 135
Self-citationMicroRNA-143 functions as a tumor suppressor in human bladder cancer T24 cells
Noguchi, S., Mori, T., Hoshino, Y., Maruo, K., Yamada, N. O., Kitade, Y., Naoe, T., & Akao, Y. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.04.005 · Cited by 132
The Clinical Utility of miR-21 as a Diagnostic and Prognostic Marker for Renal Cell Carcinoma
Faragalla, H., Youssef, Y. M., Scorilas, A., Khalil, B., White, N. M. A., Mejia‐Guerrero, S., Khella, H. W. Z., Jewett, M. A. S., Evans, A. J., Lichner, Z., et al. (2012) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2012.02.003 · Cited by 122
Improving Breast Cancer Survival Analysis through Competition-Based Multidimensional Modeling
Bilal, E., Dutkowski, J., Guinney, J., Jang, I. S., Logsdon, B. A., Pandey, G. S., Sauerwine, B., Shimoni, Y., Vollan, H. K. M., Mecham, B. H., et al. (2013) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003047 · Cited by 115
Self-citationIdentification of Clinically Useful Cancer Prognostic Factors: What Are We Missing?
McShane, L. M., Altman, D. G., & Sauerbrei, W. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji193 · Cited by 79
A microRNA survival signature (MiSS) for advanced ovarian cancer
Shih, K. K., Qin, L., Tanner, E. J., Zhou, Q. C., Bisogna, M., Dao, F., Olvera, N., Viale, A. J., Barakat, R. R., & Levine, D. A. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.01.025 · Cited by 77
MicroRNA-143 functions as a tumor suppressor in human esophageal squamous cell carcinoma.
Ni, Y., Meng, L., Wang, L.-G., Dong, W., Shen, H.-C., Wang, G.-H., Liu, Q., & Du, J.-J. (2013) · Gene · doi:10.1016/j.gene.2012.12.031 · Cited by 75
Hsa-let-7a functions as a tumor suppressor in renal cell carcinoma cell lines by targeting c-myc
Liu, Y., Yin, B., Zhang, C., Zhou, L., & Fan, J. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.11.119 · Cited by 69
Sakurai, T., Bilim, V. N., Ugolkov, A. V., Yuuki, K., Tsukigi, M., Motoyama, T., & Tomita, Y. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.05.035 · Cited by 57
Predicting the lethal phenotype of the knockout mouse by integrating comprehensive genomic data
Yuan, Y., Xu, Y., Xu, J., Ball, R. L., & Liang, H. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts120 · Cited by 44
Self-citationAntoon, J. W., Lai, R., Struckhoff, A. P., Nitschke, A., Elliott, S. G., Martin, E. C., Rhodes, L. V., Yoon, N. S., Salvo, V. A., Shan, B., et al. (2012) · Scientific Reports · doi:10.1038/srep00539 · Cited by 40
Use of personalized molecular biomarkers in the clinical care of adults with glioblastomas
Holdhoff, M., Ye, X., Blakeley, J. O., Blair, L., Burger, P. C., Grossman, S. A., & Diaz, L. A. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-012-0968-3 · Cited by 27
Lander, E. S. (2014) · PMC · Cited by 3
Lipton (1995) · Pure Amsterdam UMC · doi:10.1002/1097-0142(19950415)75:8 · Cited by 1
Harrell, F., Jr. (1996) · doi:10.1002/(sici)1097-0258(19960229)15:4<361::aid-sim168>3.0.co;2-4
Cited by
The prognostic landscape of genes and infiltrating immune cells across human cancers
Gentles, A. J., Newman, A. M., Liu, C. L., Bratman, S. V., Feng, W., Kim, D., Nair, V. S., Xu, Y., Khuong, A., Hoang, C. D., et al. (2015) · Nature Medicine · doi:10.1038/nm.3909 · Cited by 3,118
Self-citationThe landscape of genomic alterations across childhood cancers
ICGC PedBrain-Seq Project, Gröbner, S. N., ICGC MMML-Seq Project, Worst, B. C., Weischenfeldt, J., Buchhalter, I., Kleinheinz, K., Rudneva, V. A., Johann, P. D., Balasubramanian, G. P., et al. (2018) · Nature · doi:10.1038/nature25480 · Cited by 1,572
Subclonal diversification of primary breast cancer revealed by multiregion sequencing
Yates, L. R., Gerstung, M., Knappskog, S., Desmedt, C., Gundem, G., Van Loo, P., Aas, T., Alexandrov, L. B., Larsimont, D., Davies, H., et al. (2015) · Nature Medicine · doi:10.1038/nm.3886 · Cited by 816
Pan-cancer analysis of the extent and consequences of intratumor heterogeneity
Andor, N., Graham, T. A., Jansen, M., Xia, L. C., Aktipis, C. A., Petritsch, C., Ji, H. P., & Maley, C. C. (2016) · Nature Medicine · doi:10.1038/nm.3984 · Cited by 768
A pan-cancer proteomic perspective on The Cancer Genome Atlas
Akbani, R., Ng, P. K. S., Werner, H. M. J., Shahmoradgoli, M., Zhang, F., Ju, Z., Liu, W., Yang, J.-Y., Yoshihara, K., Li, J., et al. (2014) · Nature Communications · doi:10.1038/ncomms4887 · Cited by 607
Self-citation
Metadata
- Authors
- Yuan, Y., Van Allen, E. M., Omberg, L., Wagle, N., Amin-Mansour, A., Sokolov, A., Byers, L. A., Xu, Y., Hess, K. R., Diao, L., Han, L., Huang, X., Lawrence, M. S., Weinstein, J. N., Stuart, J. M., Mills, G. B., Garraway, L. A., Margolin, A. A., Getz, G., & Liang, H.
- Venue
- Nature Biotechnology
- Published
- 2014-06-22
- Volume
- 32
- Issue
- 7
- Pages
- 644-652
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W2130448611
- Cited by
- 280
- References
- 53
- FWCI
- 11.76
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.